Selected research
Industry Research
Blood Anticoagulant Industry Research Report 2026
Market perspective
The global Blood Anticoagulant market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Blood Anticoagulant is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Blood Anticoagulant is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Blood Anticoagulant is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Blood Anticoagulant include Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Keryx Biopharmaceuticals, AstraZeneca, Bayer, Pfizer, Eli Lilly and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Blood Anticoagulant market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Blood Anticoagulant Market by Company
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Keryx Biopharmaceuticals
AstraZeneca
Bayer
Pfizer
Eli Lilly
Johnson & Johnson
Sanofi
Blood Anticoagulant Segment by Type
Oral
Injection
Blood Anticoagulant Segment by Application
Hospital
Clinic
Others
Blood Anticoagulant Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Anticoagulant market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Anticoagulant and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Anticoagulant.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Blood Anticoagulant manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Blood Anticoagulant by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Blood Anticoagulant in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Clinic
- Others
Companies covered
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Keryx Biopharmaceuticals
- AstraZeneca
- Bayer
- Pfizer
- Eli Lilly
- Johnson & Johnson
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Blood Anticoagulant Market Size (2021-2032)
- 2.2.2 Global Blood Anticoagulant Sales (2021-2032)
- 2.2.3 Global Blood Anticoagulant Market Average Price (2021-2032)
- 2.3 Blood Anticoagulant by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injection
- 2.4 Blood Anticoagulant by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Blood Anticoagulant Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Blood Anticoagulant Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Blood Anticoagulant Revenue of Manufacturers (2021-2026)
- 3.4 Global Blood Anticoagulant Average Price by Manufacturers (2021-2026)
- 3.5 Global Blood Anticoagulant Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Blood Anticoagulant, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Blood Anticoagulant, Product Type & Application
- 3.8 Global Manufacturers of Blood Anticoagulant, Established Date
- 3.9 Global Blood Anticoagulant Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boehringer Ingelheim
- 4.1.1 Boehringer Ingelheim Company Information
- 4.1.2 Boehringer Ingelheim Business Overview
- 4.1.3 Boehringer Ingelheim Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boehringer Ingelheim Blood Anticoagulant Product Portfolio
- 4.1.5 Boehringer Ingelheim Recent Developments
- 4.2 Bristol-Myers Squibb
- 4.2.1 Bristol-Myers Squibb Company Information
- 4.2.2 Bristol-Myers Squibb Business Overview
- 4.2.3 Bristol-Myers Squibb Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Blood Anticoagulant Product Portfolio
- 4.2.5 Bristol-Myers Squibb Recent Developments
- 4.3 Daiichi Sankyo
- 4.3.1 Daiichi Sankyo Company Information
- 4.3.2 Daiichi Sankyo Business Overview
- 4.3.3 Daiichi Sankyo Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Daiichi Sankyo Blood Anticoagulant Product Portfolio
- 4.3.5 Daiichi Sankyo Recent Developments
- 4.4 Keryx Biopharmaceuticals
- 4.4.1 Keryx Biopharmaceuticals Company Information
- 4.4.2 Keryx Biopharmaceuticals Business Overview
- 4.4.3 Keryx Biopharmaceuticals Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Keryx Biopharmaceuticals Blood Anticoagulant Product Portfolio
- 4.4.5 Keryx Biopharmaceuticals Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca Blood Anticoagulant Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Blood Anticoagulant Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Blood Anticoagulant Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Blood Anticoagulant Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Johnson & Johnson
- 4.9.1 Johnson & Johnson Company Information
- 4.9.2 Johnson & Johnson Business Overview
- 4.9.3 Johnson & Johnson Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Johnson & Johnson Blood Anticoagulant Product Portfolio
- 4.9.5 Johnson & Johnson Recent Developments
- 4.10 Sanofi
- 4.10.1 Sanofi Company Information
- 4.10.2 Sanofi Business Overview
- 4.10.3 Sanofi Blood Anticoagulant Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanofi Blood Anticoagulant Product Portfolio
- 4.10.5 Sanofi Recent Developments
5 Global Blood Anticoagulant Market Scenario by Region
- 5.1 Global Blood Anticoagulant Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Blood Anticoagulant Sales by Region: 2021-2032
- 5.2.1 Global Blood Anticoagulant Sales by Region: 2021-2026
- 5.2.2 Global Blood Anticoagulant Sales by Region: 2027-2032
- 5.3 Global Blood Anticoagulant Revenue by Region: 2021-2032
- 5.3.1 Global Blood Anticoagulant Revenue by Region: 2021-2026
- 5.3.2 Global Blood Anticoagulant Revenue by Region: 2027-2032
- 5.4 North America Blood Anticoagulant Market Facts & Figures by Country
- 5.4.1 North America Blood Anticoagulant Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Blood Anticoagulant Sales by Country (2021-2032)
- 5.4.3 North America Blood Anticoagulant Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Blood Anticoagulant Market Facts & Figures by Country
- 5.5.1 Europe Blood Anticoagulant Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Blood Anticoagulant Sales by Country (2021-2032)
- 5.5.3 Europe Blood Anticoagulant Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Blood Anticoagulant Market Facts & Figures by Country
- 5.6.1 Asia Pacific Blood Anticoagulant Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Blood Anticoagulant Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Blood Anticoagulant Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Blood Anticoagulant Market Facts & Figures by Country
- 5.7.1 South America Blood Anticoagulant Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Blood Anticoagulant Sales by Country (2021-2032)
- 5.7.3 South America Blood Anticoagulant Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Blood Anticoagulant Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Blood Anticoagulant Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Blood Anticoagulant Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Blood Anticoagulant Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Blood Anticoagulant Sales by Type (2021-2032)
- 6.1.1 Global Blood Anticoagulant Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Blood Anticoagulant Sales Market Share by Type (2021-2032)
- 6.2 Global Blood Anticoagulant Revenue by Type (2021-2032)
- 6.2.1 Global Blood Anticoagulant Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Blood Anticoagulant Revenue Market Share by Type (2021-2032)
- 6.3 Global Blood Anticoagulant Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Blood Anticoagulant Sales by Application (2021-2032)
- 7.1.1 Global Blood Anticoagulant Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Blood Anticoagulant Sales Market Share by Application (2021-2032)
- 7.2 Global Blood Anticoagulant Revenue by Application (2021-2032)
- 7.2.1 Global Blood Anticoagulant Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Blood Anticoagulant Revenue Market Share by Application (2021-2032)
- 7.3 Global Blood Anticoagulant Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Blood Anticoagulant Value Chain Analysis
- 8.1.1 Blood Anticoagulant Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Blood Anticoagulant Production Mode & Process
- 8.2 Blood Anticoagulant Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Blood Anticoagulant Distributors
- 8.2.3 Blood Anticoagulant Customers
9 Global Blood Anticoagulant Analyzing Market Dynamics
- 9.1 Blood Anticoagulant Industry Trends
- 9.2 Blood Anticoagulant Industry Drivers
- 9.3 Blood Anticoagulant Industry Opportunities and Challenges
- 9.4 Blood Anticoagulant Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst